Clinical trials: Severe Chronic Obstructive Pulmonary Disease
COPD
Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
The overall objective is to asses the bronchodilator effect of Tiotropium/Salmeterol/Fluticasone combination delivered via Discair® twice daily as compared with original products Seretide Diskus 500 mcg Inhalation Powder twice…
- Trial name
- NCT03395002
- Testing
- Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder, Tiotropium 18 mcg Inhalation Powder, Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease With Exacerbation
Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype
"The study is a randomized controlled trial comparing roflumilast and azithromycin as add-on therapies in 70 patients with severe chronic obstructive pulmonary disease (COPD ) and frequent exacerbations.
- Trial name
- COPD (NCT07795086)
- Testing
- Roflumilast Oral Tablet, Azithromycin 250 mg
- Volunteers
- 70 people
- Sponsor
- Sidra Aziz
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.
- Trial name
- ERASE PH-COPD (NCT05844462)
- Testing
- Tadalafil
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Low Back Pain, Neuropathic Pain
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and…
- Trial name
- NCT01352741
- Testing
- Tapentadol Prolonged Release, Tapentadol Prolonged Release with Pregabalin, Tapentadol Prolonged Release open label maintenance
- Where
- 59 sites in Austria, Belgium and 5 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Chronic Obstructive Pulmonary Disease (COPD)
129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol…
- Trial name
- MUST (NCT07192016)
- Testing
- fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Chronic Graft Versus Host Disease
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells.
- Trial name
- NCT02461134
- Testing
- Ponesimod
- Volunteers
- 1 people
- Sponsor
- Actelion
COPD
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in patients with moderate to very severe chronic obstructive…
- Trial name
- NCT01043601
- Testing
- Inhaled PT005, Formoterol Fumarate 12 µg (Foradil Aerolizer)
- Where
- United States
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- SECURE2 (NCT01415518)
- Testing
- Drug: Budesonide/formoterol (Symbicort Turbuhaler, Drug: ipratropium (AtroventTM), theophylline SR
- Where
- 21 sites in China
- Volunteers
- 581 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with…
- Trial name
- SECURE 1 (NCT01397890)
- Testing
- Budesonide/formoterol (Symbicort® Turbuhaler®), Tiotropium (SpirivaTM)
- Where
- 31 sites in China, Hong Kong and 3 more
- Volunteers
- 793 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine whether inhalation of Bimosiamose is safe and effective in the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01108913
- Testing
- Bimosiamose
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Revotar Biopharmaceuticals AG
Chronic Obstructive Pulmonary Disease
Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is characterized by lung hyperinflation and flow limitation. These physiopathological modifications are secondary to loss of elastic recoil and bronchial obstruction due to emphysema.
- Trial name
- NCT02181023
- Testing
- Aclidinium Bromide, Glycopyrronium Bromide
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- University of Milan
Emphysema, COPD
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)
This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll up to 140 subjects with severe emphysema and collateral ventilation in the target…
- Conditions
- Emphysema, COPD, Severe Emphysema
- Trial name
- CONVERT (NCT04559464)
- Testing
- AeriSeal, Zephyr Valves
- Where
- 14 sites in Australia, France and 5 more
- Volunteers
- 102 people
- Sponsor
- Pulmonx Corporation
Pulmonary Disease, Chronic Obstructive
Simvastatin Therapy for Moderate and Severe COPD
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to…
- Trial name
- STATCOPE (NCT01061671)
- Testing
- simvastatin
- Where
- 51 sites in United States, Canada
- Volunteers
- 885 people
- Sponsor
- University of Minnesota
Diaphragm Electrical Activity, COPD (Chronic Obstructive Pulmonary Disease)
Effect of Electrical Diaphragmatic Stimulation on Chronic Obstructive Pulmonary Disease
Respiratory muscle dysfunction is a common consequence of chronic obstructive pulmonary disease (COPD). This technique consists of placing electrodes on the skin at locations near the motor points of the diaphragm, transmitting…
- Trial name
- NCT07020299
- Testing
- Device : Digital electrical muscle stimulator is applied to induce diaphragm contraction.
- Where
- Egypt
- Volunteers
- 128 people
- Sponsor
- Mansoura University Hospital
Pulmonary Emphysema
Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils
The study hypothesis is that patients with homogeneous emphysema behave differently compared to heterogeneous emphysema with respect to exercise capacity.
- Trial name
- CYCLONE (NCT02879331)
- Testing
- 10 coils in upper lobes, 15 coils in upper and lower lobes, cycloergometry
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study of RC1416 Injection in COPD
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07402551
- Testing
- RC1416
- Where
- 46 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft Versus Host Disease
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and…
- Trial name
- NCT04944043
- Testing
- TQ05105 Tablet
- Where
- 12 sites in China
- Volunteers
- 45 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.